BackZyVersa Therapeutics Overview

ZyVersa Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$57.62M
77.74% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$911.85M
31.06% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

ZyVersa Therapeutics (ZVSA) FAQ

Stockcircle tracks research & development for ZyVersa Therapeutics (ZVSA), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for ZyVersa Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main ZVSA overview so you can move from this figure to the surrounding analysis quickly.